{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:29:29Z","timestamp":1789349369640,"version":"build-2803163510"},"reference-count":37,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1701,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1365-2710.2009.01150.x","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T10:25:14Z","timestamp":1268821514000},"page":"1-9","source":"Crossref","is-referenced-by-count":51,"title":["Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics"],"prefix":"10.1155","volume":"36","author":[{"given":"T. C.","family":"Pomfret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Gagnon Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.4049\/jimmunol.156.10.3579","article-title":"Novel vaccine approaches","volume":"156","author":"Ertl","year":"1996","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1111\/j.1365-2710.2009.01150.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1363\/3600604","article-title":"Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000","volume":"36","author":"Weinstock","year":"2004","journal-title":"Perspectives on Sexual and Reproductive Health"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB3|cit3","unstructured":"Centers for Disease Control and Prevention 2006 Sexually Transmitted Diseases Treatment Guidelines, 2006 1 94"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB4|cit4","volume-title":"United States Cancer Statistics: 2004 Incidence and Mortality [Internet]","author":"U.S. Cancer Statistics Working Group","year":"2007"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Human papillomavirus and cervical cancer - burden and assessment of causality","volume":"31","author":"Bosch","year":"2003","journal-title":"Journal of the National Cancer Institute Monographs"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/JCM.33.8.2058-2063.1995","article-title":"Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts","volume":"33","author":"Greer","year":"1995","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB7|cit7","volume-title":"NCI factsheet: human papillomavirus (HPV) vaccines: questions and answers [Internet]","author":"National Cancer Institute","year":"2007"},{"issue":"1","key":"10.1111\/j.1365-2710.2009.01150.x-BIB8|cit8","first-page":"52","article-title":"Cancer of the uterine cervix and human papillomavirus infection","volume":"78","author":"Das","year":"2000","journal-title":"Current Science"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB9|cit9","volume-title":"Vaccines and preventable diseases: HPV vaccine - Questions & answers for the public about the safety and effectiveness of the human papillomavirus (HPV) vaccine [Internet]","author":"Centers for Disease Control and Prevention","year":"2008"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB10|cit10","unstructured":"Merck & Co. Gardasil \u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] Requested Information Merck & Co."},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB11|cit11","unstructured":"Centers for Disease Control and Prevention Reports of health concerns following HPV vaccination [Internet] Department of Health and Human Services: Centers for Disease Control and Prevention http:\/\/www.cdc.gov\/vaccinesafety\/Vaccines\/HPV\/gardasil.html"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB12|cit12","volume-title":"Gardasil\u00ae [package insert on the Internet]","author":"Merck & Co., Inc","year":"2009"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB13|cit13","unstructured":"Department of Health and Human Services\/Centers for Disease and Prevention 2008 Advisory Committee on Immunizations Practices (ACIP) Summary Report http:\/\/www.cdc.gov\/vaccines\/recs\/acip\/downloads\/min-oct08.pdf"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB14|cit14","volume-title":"Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL\u00ae in Women Ages 27 through 45 [Internet]","author":"Merck & Co., Inc","year":"2009"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB15|cit15","volume-title":"GARDASIL\u00ae, Merck\u2019s Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study [Internet]","author":"Merck & Co., Inc","year":"2009"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB16|cit16","unstructured":"Rockoff JD 2009 Merck Seeks FDA Approval for Gardasil in Boys [Internet]. The Wall Street Journal; January 5 http:\/\/blogs.wsj.com\/health\/2009\/01\/05\/merck-seeks-fda-approval-for-gardasil-in-boys\/"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"s24","DOI":"10.1016\/j.ygyno.2007.07.075","article-title":"Human papillomavirus vaccination in males","volume":"107","author":"Giuliano","year":"2007","journal-title":"Gynecologic Oncology"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/GCO.0b013e3282f1a91b","article-title":"Human papillomavirus vaccine: more than a vaccine","volume":"10","author":"Pallecarcos","year":"2007","journal-title":"Current Opinion in Obstetrics and Gynecology"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MOP.0b013e328305e298","article-title":"Human papillomavirus vaccine: recommendations, issues and controversies","volume":"20","author":"Fisher","year":"2008","journal-title":"Current Opinion in Pediatrics"},{"issue":"19","key":"10.1111\/j.1365-2710.2009.01150.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"19","key":"10.1111\/j.1365-2710.2009.01150.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE II Study Group","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/521679","article-title":"Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine","volume":"196","author":"Giuliano","year":"2007","journal-title":"The Journal of Infectious Diseases"},{"issue":"3","key":"10.1111\/j.1365-2710.2009.01150.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 La virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"The Pediatric Infectious Disease Journal"},{"issue":"3","key":"10.1111\/j.1365-2710.2009.01150.x-BIB24|cit24","first-page":"261","article-title":"Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women","volume":"193","author":"Barr","year":"2008","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"RR02","key":"10.1111\/j.1365-2710.2009.01150.x-BIB25|cit25","first-page":"1","article-title":"Quadrivalent Human Papillomavirus Vaccine; Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB26|cit26","volume-title":"New Vaccine Criteria for U.S. Immigration. [Internet]","author":"Centers for Disease Control and Prevention","year":"2009"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB28|cit28","unstructured":"Centers for Disease Control and Prevention 2008 CDC Statement on the cost-effectiveness of HPV Vaccine; August 28 http:\/\/www.cdc.gov\/vaccines\/vpd-vac\/hpv\/cost-effect-hpv-vac.htm"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB29|cit29","unstructured":"Cervarix\u00ae [package insert] 2009 GlaxoSmithKline Biologicals"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB30|cit30","volume-title":"Landmark study for GSK\u2019s cervical cancer vaccine published in The Lancet; Largest efficacy trial of a cervical cancer vaccine showed Cervarix\u00ae protects against the five most common cancer-causing virus types [Internet]","author":"GlaxoSmithKline Biologicals, S.A.","year":"2009"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB31|cit31","volume-title":"FDA Approves New Vaccine for the Prevention of Cervical Cancer. [Internet]","author":"Food and Drug Administration","year":"2009"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB32|cit32","volume-title":"Cervarix\u2122, GSK\u2019s cervical cancer vaccine, wins tender for UK national immunisation programme [Internet]","author":"GlaxoSmithKline Biologicals S.A.","year":"2008"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB33|cit33","volume-title":"Cervarix\u00ae provides longest duration of sustained neutralising antibodies reported for any vaccine against HPV 16 and 18 to date [Internet]","author":"GlaxoSmithKline Biologicals S.A.","year":"2008"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB34|cit34","volume-title":"GSK cervical cancer candidate vaccine Cervarix demonstrates long-term protection for more than six years [Internet]","author":"GlaxoSmithKline Biologicals S.A.","year":"2008"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB35|cit35","volume-title":"New data for GlaxoSmithKline\u2019s vaccine, Cervarix\u00ae, presented at IPV Conference [Internet]","author":"GlaxoSmithKline Biologicals S.A.","year":"2009"},{"issue":"9686","key":"10.1111\/j.1365-2710.2009.01150.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and pre-cancer caused by oncogenic HPV types: final event-driven analysis in young women (the PATRICIA trial) 2009","volume":"374","author":"Paavonen","year":"2009","journal-title":"The Lancet"},{"key":"10.1111\/j.1365-2710.2009.01150.x-BIB37|cit37","volume-title":"GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine [Internet]","author":"GlaxoSmithKline Biologicals S.A.","year":"2009"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2009.01150.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2009.01150.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T01:31:45Z","timestamp":1685496705000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2009.01150.x"}},"subtitle":["HPV Vaccine: Safety, Efficacy &amp; Pharmacoeconomics"],"short-title":[],"issued":{"date-parts":[[2011,1,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01150.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,4]]}}}